Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
General13 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News5 hours agoWhy the Brisbane City Hall clock has fallen silent
-
Noosa News17 hours agoNew One Nation branch | Noosa Today
-
Noosa News7 hours agoFederal government to review trade restrictions for Philippine banana imports